Țară: Australia
Limbă: engleză
Sursă: Department of Health (Therapeutic Goods Administration)
ceftazidime pentahydrate, Quantity: 1.164 g
Alphapharm Pty Ltd
ceftazidime pentahydrate
Injection, powder for
Excipient Ingredients: sodium carbonate
Intramuscular, Intravenous
Packs of 1 and 5 vials, Packs of 10 vials
(S4) Prescription Only Medicine
Ceftazidime Viatris is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other pseudomonal antibiotics cannot be used.. Indications include:. Severe infections in general: for example septicaemia, including neonatal sepsis, bacteraemia, and in patients in intensive care units with specific problems, eg, infected burns.. Respiratory tract infections: for example, pneumonia, broncho-pneumonia, infected pleurisy, infected bronchiectasis and bronchitis.. Severe ear, nose and throat infections: for example, otitis media, mastoiditis.. Urinary tract infections: for example, acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), and infections associated with bladder and renal stones.. Skin and soft tissue infections: for example, erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis.. Gastrointestinal and abdominal infections: for example, intra-abdominal abscesses, enterocolitis.. Bone and joint infections: for example, osteitis, osteomyelitis, septic arthritis, infected bursitis.
Visual Identification: White or almost white, crystalline powder.; Container Type: Vial; Container Material: Glass Type III Clear; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert
Licence status A
2010-05-21
CEFTAZIDIME ALPHAPHARM _ceftazidime (as pentahydrate)_ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some common questions about CEFTAZIDIME Alphapharm. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have benefits and risks. Your doctor has weighed the risks of you being given CEFTAZIDIME Alphapharm against the benefits expected for you. IF YOU HAVE ANY CONCERNS ABOUT BEING GIVEN THIS MEDICINE, TALK TO YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET WITH YOUR MEDICINE. You may need to read it again. WHAT CEFTAZIDIME ALPHAPHARM IS USED FOR? CEFTAZIDIME Alphapharm is used to treat a wide range of infections caused by bacteria. These infections may affect the chest (bronchitis or pneumonia), ears, nose, throat, bladder and urinary tract, skin and soft tissue, stomach or bones. This medicine belongs to a group of medicines called cephalosporins. It works by killing the bacteria that cause these infections. ASK YOUR DOCTOR IF YOU HAVE ANY QUESTIONS ABOUT WHY THIS MEDICINE HAS BEEN PRESCRIBED FOR YOU. Your doctor may have prescribed it for another reason. CEFTAZIDIME Alphapharm is available only with a doctor's prescription. CEFTAZIDIME Alphapharm is not addictive. BEFORE YOU ARE GIVEN CEFTAZIDIME ALPHAPHARM _WHEN YOU MUST NOT BE GIVEN_ _IT_ YOU MUST NOT BE GIVEN CEFTAZIDIME ALPHAPHARM IF YOU HAVE EVER HAD AN ALLERGIC REACTION TO: • any medicine containing cephalosporins or penicillins • any of the ingredients listed at the end of this leaflet. Some of the symptoms of an allergic reaction may include shortness of breath; wheezing or difficulty breathing; swelling of the face, lips, tongue or other parts of the body; rash, itching or hives on the skin. YOU MUST NOT BE GIVEN THIS MEDICINE AFTER THE EXPIRY DATE PRINTED ON THE PACK OR IF THE PACKAGING IS TORN OR SHOWS SIGNS OF TAMPERING. IF YOU ARE NOT SURE WHETHER YOU SHOULD BE GIVEN THIS MEDICINE, TALK TO YOUR DOCTOR. _BEFORE YOU ARE GIVEN IT_ TELL YOUR DO Citiți documentul complet
AUSTRALIAN PRODUCT INFORMATION CEFTAZIDIME ALPHAPHARM _Ceftazidime pentahydrate powder for injection _ 1 NAME OF THE MEDICINE Ceftazidime pentahydrate 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Ceftazidime Alphapharm is supplied in vials containing 1 g and 2 g of ceftazidime (as pentahydrate). 116.4 mg ceftazidime pentahydrate is equivalent to 100 mg ceftazidime free acid. For the full list of excipients, see SECTION 6.1 LIST OF EXCIPIENTS . 3 PHARMACEUTICAL FORM Ceftazidime Alphapharm is a powder for injection and is a white or almost white, crystalline powder. On the addition of water for injections, Ceftazidime Alphapharm dissolves with effervescence to produce a solution for injection. Ceftazidime Alphapharm containing 1 g of ceftazidime (as pentahydrate) is for intramuscular or intravenous use. Ceftazidime Alphapharm containing 2 g ceftazidime (as pentahydrate) is for intravenous use. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Ceftazidime Alphapharm is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other pseudomonal antibiotics cannot be used. Indications include: SEVERE INFECTIONS IN GENERAL: for example septicaemia, including neonatal sepsis, bacteraemia, and in patients in intensive care units with specific problems, e.g., infected burns. RESPIRATORY TRACT INFECTIONS: for example, pneumonia, broncho-pneumonia, infected pleurisy, infected bronchiectasis and bronchitis. SEVERE EAR, NOSE AND THROAT INFECTIONS: for example, otitis media, mastoiditis. URINARY TRACT INFECTIONS: for example, acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), and infections associated with bladder and renal stones. SKIN AND SOFT TISSUE INFECTIONS: for example, erysipelas, abscesses, cellulitis, infected burns and woun Citiți documentul complet